Nidec Revises Upward Consolidated Fiscal First-Half and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nidec Revises Upward Consolidated Fiscal First-Half and Year-End Financial Forecasts and Dividend Projections for the Year Ending March 31, 2015

KYOTO, Japan, July 23, 2014 (GLOBE NEWSWIRE) -- Nidec Corporation (NYSE: NJ ) (the "Company") today announced an upward revision to its U.S. GAAP-based consolidated fiscal first-half and year-end financial forecasts and dividend projections for the year ending March 31, 2015, originally announced on April 22, 2014.

Revised consolidated financial forecasts (U.S. GAAP) for the six months ending September 30, 2014

From April 1, 2014 to September 30, 2014 (Millions of yen, except for per share amounts and percentages)
  For the six months ending September 30, 2014  
  Previous
forecast
(April 22, 2014)
Revised
Forecast
Change
(amount)
Change
(percent)
(Reference)
 For the six months
ended September
30, 2013
Net sales 450,000 460,000 10,000 2.2% 429,634
Operating income 45,000 50,000 5,000 11.1% 39,337
Income before taxes 44,000 49,000 5,000 11.4% 38,441
Net income attributable to Nidec Corporation 29,500 33,500 4,000 13.6% 27,103
Net income attributable to Nidec Corporation per share-basic* 106.96 121.46 -- -- 100.99

Revised consolidated financial forecasts (U.S. GAAP) for the year ending March 31, 2015

From April 1, 2014 to March 31, 2015 (Millions of yen, except for per share amounts and percentages)
  For the year ending March 31, 2015  
  Previous
forecast
(April 22, 2014)
Revised
Forecast
Change
(amount)
Change
(percent)
(Reference) 
For the year ended 
March 31, 2014
Net sales 950,000 960,000 10,000 1.1 % 875,109
Operating income 100,000 105,000 5,000 5.0 % 85,068
Income before taxes 98,000 103,000 5,000 5.1 % 84,664
Net income attributable to Nidec Corporation 65,000 69,000 4,000 6.2 % 56,404
Net income attributable to Nidec Corporation per share-basic* 235.67 250.18 -- -- 207.31

* The Company implemented a two-for-one stock split of its common stock effective April 1, 2014. The previously reported net income attributable to Nidec Corporation per share-basic has been retroactively adjusted to reflect the stock split.

Reasons for the revision for the financial forecasts

Net sales and resulting profit for the three months ended June 30, 2014 exceeded the Company's expectations at the beginning of the period. In view of the favorable quarterly results, the Company has decided to revise upward its previously announced financial performance forecasts for six months ending September 30, 2014 and the fiscal year ending March 31, 2015 largely to the extent that the three-month results exceeded its original expectations.

Notes:

The exchange rates used for the preparation of the foregoing forecasts are US$1 = JPY100 and Euro1 = JPY135. The exchange rates between the relevant Asian currencies and the Japanese yen used for the preparation of the foregoing forecasts were determined assuming these exchange rates.

Revised interim and year-end dividend projections for the year ending March 31, 2015

Dividends per share (Yen) for the year ending March 31, 2015

   
  Annual Dividends Per Share
  First
Quarter-end
Second
Quarter-end
Third
Quarter-end
Fourth
Quarter-end
Full Year
Previous projection
(as of April 22, 2014)
-- 27.50 -- 27.50 55.00
Revised projection -- 30.00 -- 30.00 60.00
Divided paid for the year
ending March 31, 2015
-- -- -- -- --
<Reference>
Dividend paid for the year
ended March 31, 2014 *
-- 45.00 -- 55.00 100.00

*The Company implemented a two-for-one stock split on its common stock as of March 31, 2014. Dividends paid for the year ended March 31, 2014 represent the actual payment amounts on a pre-split basis.

Reasons for the revision for dividend projections

The Company upholds shareholder-oriented management and places importance on regular dividend payments, seeking to increase its dividend payout to around 30% of the consolidated net income. Based on the stated upward revision to the Company's consolidated financial forecasts for the year ending March 31, 2015, the Company has revised upward both its interim and year-end dividend projections for the year ending March 31, 2015 from 27.50 yen per share to 30.00 yen per share, making the projected aggregate annual dividend 60.00 yen per share.

Cautionary Statement Concerning Forward-Looking Information

This press release contains forward-looking statements regarding the Company's current intent, plans, expectations and estimates. Such forward-looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors, including, but not limited to, changes in customer circumstances and demand, exchange rate fluctuations, available funds, future alternative uses for cash, and general economic, business and market conditions. The Company assumes no obligation to, and does not currently intend to, update these forward-looking statements, except as required by law.

Masahiro Nagayasu General Manager Investor Relations +81-75-935-6140

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading